Pancreatic Cancer Research

Clinical trialNo phase (not a drug trial)Active not recruiting

Management of Symptomatic Advanced Pancreatic Adenocarcinoma

Management of Symptomatic Advanced Pancreatic Adenocarcinoma: "Urgence Pancreas" - A Prospective A.R.CA.D Cohort Study

Outcome
Ongoing
Phase
No phase (not a drug trial)
Status
Active not recruiting
Study type
Interventional
Start
19 December 2016
Listed end
September 2025
Enrollment
110 participants
Sites
12
Primary outcomes
The rate of 14-EISCP success
Sponsor type
Academic / other
Results posted
No
Last update
13 June 2025

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This study assessed the feasibility and effects of an early integrative supportive care program in patient with advanced pancreatic adenocarcinoma (aPDAC).

Detailed description public domain (ClinicalTrials.gov)

This is a national, multicenter, prospective study, including: * A 14-day (+/-2 days) integrative supportive care program (14-EISCP) initiated as early as the clinical suspicion of aPDAC, * Follow-up period after the 14-EISCP. ECOG PS ≥2 patients with pathologically confirmed or suspected aPDAC on imaging were included at first oncology visit in the 14-EISCP including pain, nutritional, diagnostic and stenting procedures. Post-EISCP ECOG PS ≤1 patients received mFOLFIRINOX or gemcitabine/nab-paclitaxel, ECOG PS ≥2 patients received mFOLFOX7 or investigator choice chemotherapy or best supportive care.